---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-214303"
form_type: "8-K"
ticker: "SYBX"
cik: "0001527599"
company_name: "SYNLOGIC, INC."
filed_at: "2023-08-16T23:59:59+00:00"
generated_at: "2026-06-11T08:20:56.993875+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Synlogic and Roche amend collaboration; IBD option deadline extended to Jan 15, 2024 or later

## Summary
- Roche holds exclusive option to negotiate a license for Synlogic's IBD Synthetic Biotic medicine.
- Amendment extends option deadline to later of Jan 15, 2024 or 90 days after data delivery.
- Original collaboration agreement effective June 16, 2021; amendment executed August 16, 2023.
- Synlogic to deliver certain research data before the 90-day extension trigger.
- No other changes to collaboration terms were disclosed.

## SEC filing metadata
- accession: 0001193125-23-214303
- form_type: 8-K
- ticker: SYBX
- cik: 0001527599
- company_name: SYNLOGIC, INC.
- filed_at: 2023-08-16T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 1.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1527599/000119312523214303/0001193125-23-214303-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1527599/000119312523214303/d539351d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-214303
- JSON: https://secwatch.observer/filing/0001193125-23-214303.json
- Plain text: https://secwatch.observer/filing/0001193125-23-214303.txt

## Key facts
- Material Agreements
  SYNLOGIC, INC. amended Amendment to Pilot Collaboration and Option Agreement with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc. (effective 2023-08-16).
  - Action: amendment
  - Agreement: collaboration
  - Counterparty: F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc.
  - Effective: 2023-08-16
  source text: On August 16, 2023, Synlogic Operating Company, Inc. (“Synlogic OpCo”), a wholly-owned subsidiary of Synlogic, Inc. (the “Company”), F. Hoffmann-La Roche Ltd (“Roche Basel”) and Hoffmann-La Roche Inc. (“Roche US”, and together with Roche Basel, “Roche”) entered into an amendment (the “Amendment”) to the Pilot Collaboration and Option Agreement (the “Roche Collaboration and Option Agreement”), effective as of June 16, 2021, by and between Synlogic OpCo and Roche.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1527599/000119312523214303/0001193125-23-214303-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.